Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Non Small Cell Lung Cancer
Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease
The investigators hypothesized that NSCL patients receiving therapy based on their baseline tumor markers levels would attain higher response rates than patients in the control arm receiving non customized therapy.
- Trial name
- CONTEST (NCT01784549)
- Testing
- Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine
- Where
- Italy
- Volunteers
- 168 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Lung Cancer
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544648
- Testing
- carboplatin, nab-paclitaxel, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Cancer
Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899535
- Testing
- DNA analysis, RNA analysis, microarray analysis
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Cognitive/Functional Effects
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer
RATIONALE: Questionnaires that assess symptoms caused by cancer and cancer therapy may help improve the ability to plan treatment for patients with invasive cancer to help them live longer and more comfortably.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00303914
- Testing
- assessment of therapy complications, cognitive assessment, psychosocial assessment and care
- Where
- 32 sites in United States
- Volunteers
- 2,310 people
- Sponsor
- Eastern Cooperative Oncology Group
ALK Gene Rearrangement, ALK Gene Translocation
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma…
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02201992
- Testing
- Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
- Where
- 1,618 sites in United States, Guam and 1 more
- Volunteers
- 166 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lung Cancer
Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897234
- Testing
- Mass Spectrometry
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT03191149
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test
- Where
- 347 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Stage II Lung Cancer, Lung Cancer
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.
- Conditions
- Stage II Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer, NSCLC
- Trial name
- PERCC (NCT07412041)
- Testing
- PERCC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Locally Advanced Non Small-Cell Lung Canger
Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer
Nitroglycerin will increase the effectiveness of treatment with induction chemotherapy and concurrent chemo-radiotherapy by reducing chemo-radio resistance through an increased oxygen pressure in tumoral tissue.
- Trial name
- NCT00886405
- Testing
- Transdermal nitroglycerin
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- National Institute of Cancerología
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Immunotherapy
Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
This phase 1b/2a study evaluates the safety, feasibility, and efficacy of combining dupilumab (anti-IL-4Rα) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
- Trial name
- Dupi-Cemi (NCT06743581)
- Testing
- Cemiplimab, Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Lung Cancer
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004202
- Testing
- carboplatin, chemotherapy, efaproxiral
- Where
- 16 sites in United States, Canada
- Sponsor
- Spectrum Pharmaceuticals, Inc
Resectable NSCLC, KRAS G12C Mutation
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
This is an exploratory study evaluating the efficacy and safety of neoadjuvant therapy with fulzerasib sequentially combined with sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small cell lung…
- Conditions
- Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
- Trial name
- K-NADIR (NCT07492342)
- Testing
- fulzerasib
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Jianxing He
Non-Small Cell Lung Cancer
A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT07594522
- Testing
- Photon or Proton standard stereotactic body radiotherapy (SBRT), Ivonescimab
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine
The primary objective of this study is to demonstrate an improvement in Progression-Free Survival (PFS) for the combination of vandetanib plus gemcitabine compared with gemcitabine plus placebo in chemonaïve (not including an…
- Trial name
- ZELIG (NCT00753714)
- Testing
- ZD6474, Vandetanib, Gemcitabine
- Where
- 15 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Genzyme, a Sanofi Company
Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
This phase II trial studies how well stereotactic body radiation therapy with or without nivolumab works in treating patients with stage I-IIA non-small cell lung cancer or cancer that has come back.
- Conditions
- Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm, Lung Non-Small Cell Squamous Carcinoma, Minimally Invasive Lung Adenocarcinoma
- Trial name
- NCT03110978
- Testing
- Nivolumab, Stereotactic Body Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)
Primary goal of the study is to assess the overall survival of the addition of hypofractionated image guided radiotherapy concurrently with Docetaxel and cisplatin.
- Trial name
- SMART (NCT00887315)
- Testing
- Docetaxel and cisplatin, Docetaxel and cisplatin Plus Hypofractionated Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Chicago
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent).
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT04268550
- Testing
- Selpercatinib
- Where
- 306 sites in United States
- Volunteers
- 124 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Colorectal Cancer
Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer
RATIONALE: Collecting information over time about patients' and health care providers' understanding of pain and fatigue and providing education about pain and fatigue management may improve quality of life.
- Conditions
- Breast Cancer, Colorectal Cancer, Fatigue, Lung Cancer
- Trial name
- NCT00900835
- Testing
- educational intervention, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United States
- Volunteers
- 470 people
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer Stage IV
Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
This is a multicenter, national, nonrandomized, phase II trial in subjects with nonsquamous NSCLC patients that have untreated asymptomatic BM.
- Trial name
- ATEZO-BRAIN (NCT03526900)
- Testing
- Atezolizumab
- Where
- 15 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Spanish Lung Cancer Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.